The Biosimilars Group founded today by 5 service providers dedicated to biosimilar development
July 9, 2014 / Today the 5 pharmaceutical service providers Assign GmbH, Aurigon GmbH, Celonic AG , Protagen Protein Services GmbH and PharmaLex GmbH have founded The Biosimilars Group GmbH. The Biosimilars Group will be dedicated to provide development services for biosimilars from cell to marketing authorization.
In a meeting in Mannheim, Germany, Dr. Klaus Fischer, Managing Director, Assign, Dr. Gerhard Hager, Managing Director, Aurigon, Dr. Roland Meisel, Director Business Development, Celonic, Martin Blüggel, Managing Director, Protagen Protein Services and Dr. Tilo Netzer, Chief Operating Officer, PharmaLex have signed the contract for establishing The Biosimilars Group.
“We are proud that with The Biosimilars Group we can provide unique expert support to our customers in the pharmaceutical industry” says Dr. Roland Meisel who will be responsible for Manufacturing at The Biosimilars Group and Dr. Klaus Fischer, representing Clinical Operations explains “The Biosimilars Group will be covering all aspects of biosimilar development from candidate identification to marketed product”. “At the same time our customers can choose any combination of services which they need. Thus, we are providing them with a tailor-made service” adds Dr. Gerhard Hager, Nonclinical Expert at The Biosimilars Group.
Of note, The Biosimilars Group will not develop own biosimilar products for partnering.
The founding members of The Biosimilars Group are all renowned service providers with a track record in biosimilars development. They have successfully completed over 80 projects across all functions in the past 5 years and have more than 10 years of experience in biosimilar development. Overall, there are more than 500 highly qualified professionals in the group. The partner companies are operating more than 15 sites on three continents.